Miraculins Licenses Preeclampsia Biomarker Panel from Mount Sinai

Aug 07, 2008

NEW YORK (GenomeWeb News) – Diagnostics developer Miraculins has agreed to license a panel of biomarkers from Mount Sinai Hospital that it will use to develop diagnostic assays to detect preecleampsia, the company said today.

These markers have shown evidence that they may help to diagnose the disease in its earliest stages, Winnipeg, Manitoba-based Miraculins said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Main menu